Evidence map›Paper›PMID 34038700›Full record

ArticleJournal of biomolecular structure & dynamics2022

Engineering a multi epitope vaccine against SARS-CoV-2 by exploiting its non structural and structural proteins.

Vikrant Singh Rajput, Ritika Sharma, Anchala Kumari, Nidhi Vyas, Vijay Prajapati, Abhinav Grover

Open access · greenAbstract read
In one paragraph

Article in Journal of biomolecular structure & dynamics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. A novel vaccine based on SARS-CoV-2 CD4Scientific reports · 2022
    Article
  9. Article
  10. Development of synthetic antigen vaccines for COVID-19.Human vaccines & immunotherapeutics · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Vikrant Singh RajputSchool of Biotechnology, Jawaharlal Nehru University (JNU), Delhi, India.
Ritika SharmaSchool of Biotechnology, Jawaharlal Nehru University (JNU), Delhi, India.
Anchala KumariSchool of Biotechnology, Jawaharlal Nehru University (JNU), Delhi, India.
Nidhi VyasSchool of Biotechnology, Jawaharlal Nehru University (JNU), Delhi, India.
Vijay PrajapatiDepartment of Biochemistry, School of Life Sciences, Central University of Rajasthan, Ajmer, Rajasthan, India.ORCID 0000-0001-6510-0596
Abhinav GroverSchool of Biotechnology, Jawaharlal Nehru University (JNU), Delhi, India.ORCID 0000-0002-3296-7860
Jawaharlal Nehru University · INCentral University of Rajasthan · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SARS-CoV-2, the causative agent behind the ongoing pandemic exhibits an enhanced potential for infection when compared to its related family members- the SARS-CoV and MERS-CoV; which have caused similar disease outbreaks in the past. The severity of the global health burden, increasing mortality rate and the emergent economic crisis urgently demands the development of next generation vaccines. Amongst such emergent next generation vaccines are the multi-epitope subunit vaccines, which hold promise in combating deadly pathogens. In this study we have exploited immunoinformatics applications to delineate a vaccine candidate possessing multiple B and T cells epitopes by utilizing the SARS-CoV-2 non structural and structural proteins. The antigenicity potential, safety, structural stability and the production feasibility of the designed construct was evaluated computationally. Furthermore, due to the known role of human TLR-3 immune receptor in viral sensing, which facilitates host cells activation for an immune response, the vaccine construct was examined for its binding efficiency using molecular docking and molecular dynamics simulation studies, which resulted in strong and stable interactions. Finally, the immune simulation studies suggested an effective immune response on vaccine administration. Overall, the immunoinformatics analysis advocates that the proposed vaccine candidate is safe and immunogenic and therefore can be pushed as a lead for

Indexed as

COVID-19Viral VaccinesCOVID-19 VaccinesEpitopes, B-LymphocyteEpitopes, T-LymphocyteHumansImmunogenicity, VaccineMolecular Docking SimulationSARS-CoV-2Vaccines, SubunitCOVID-19 VaccinesEpitopes, B-LymphocyteEpitopes, T-LymphocyteVaccines, SubunitViral VaccinesdockingimmunoinformaticsMD simulationmulti-epitopeSARS-COV-2vaccine

Identifiers

PMID34038700
PMCPMC8171004
OpenAlexW3165459542

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.